For questions regarding claiming CME Credit, please refer to our FAQ section.




Post TCT 2015 - Banner

Program Overview:

In a double-bind randomized study of 2.466 patients at high risk of bleeding, using 1 month of dual antiplatelet therapy (DAPT) and the BioFreedom polymer-free BiolimusA9 (BA9) drug-coated stents (DCS) is safer and more effective than using a bare metal stent (BMS).   The LEADERS FREE trial included a subset of patients normally excluded from studies due to higher co-morbidities and higher event rates. This group was evaluated on the incidence of myocardial infarction, cardiac death and stent thrombosis as a primary endpoint .The difference in MI and cardiac death was lower in those receiving a DCS. Patients requiring target lesion revascularization was decreased in those with the use of DCS and DAPT for 1 month.. The results showed that patients that are at high risk of bleeding during PCI benefit from the use of BioFreedom DCS. Data from this research has found that this new technology and treatment will help those patients with a high bleeding risk.

In the 10-year follow up questions as to whether or not the treatment to use PFO closure was beneficial for all strokes. This new data has shown that the use of PFO reduces the risk for recurrent strokes in patients under the age of 60 and has a high procedural success. The long-term effects of the PFO closure are safe and effective in preventing cryptogenic strokes in patients less than 60. The Amplatzer is a closure device used in patients that have had a cryptogenic ischemic stroke and needed closure of the patent foramen ovale. (PFO) The original RESPECT trial was a 980-person trial that showed PFO closure is superior to medical management alone.  This original trial missed the end points of significant risk reduction in the intention to treat population, which prompted a long-term review. The long-term results confirmed that the use the Amplatzer PFO occluder in carefully selected patients was successful in reducing reoccurring strokes in these patients.  


Click Here to access this CME Program   
Release Date:
January 22, 2016

Expiration Date:
July 22, 2016 

Estimated Time:
1 hour    
 
 
Volcano Banner 200x100

Program Overview:

Atrial fibrillation, a condition affecting millions of patients worldwide, is associated with increased risks of stroke and mortality that complicate the risk-benefit profile of patients who undergo PCI. Management options include not only warfarin but also a growing array of novel anticoagulants that aim to reduce the need for monitoring and improve safety and efficacy.


Click Here to access this CME Program   
Release Date:
November 20th, 2015

Expiration Date:
May 20th, 2016 

Estimated Time:
1 hour    
 


Post ESC 2015 Banner: MATRIX Duration, OPTIDUAL and PLATFORM

Program Overview:

Current controversies, such as the choice of antithrombin during PCI, the duration of dual antiplatelet therapy (DAPT), and the identification of PCI candidates among stable CAD patients, will be explored during this one-hour webcast. The MATRIX Treatment Duration study compared outcomes with of bivalirudin and heparin use among 7,000 European ACS patients and also examined the impact of post- PCI bivalirudin infusion. Next, the OPTIDUAL trial examined the impact of DAPT use for up to 4 years after PCI in patients free of adverse events in the first year. Finally, the PLATFORM study examined the utility of CT-derived FFR for patients with stable coronary artery disease. 


Click Here to access this CME Program   
Release Date:
November 23, 2015

Expiration Date:
May 23, 2016 

Estimated Time:
1 hour